Your end-to-end CDMO partner
for your viral vector projects
We are a pure play CDMO, specialized in development and manufacturing of viral vectors.
From development to market, we provide GMP viral vectors, contributing to the success of our clients’ immunotherapies and gene therapy innovations.
We have been a pioneer in developing and producing viral vectors since 1994.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.
As a pure CDMO player, we contribute to the success of your immunotherapy and gene therapy innovations.
By Gaelle Besomi
/ 21 September 2023
Oxford Biomedica, a leading quality and innovation-led cell and gene therapy Contract Development Manufacturing Organization, and Institut Mérieux announce that...
Read More
By Gaelle Besomi
/ 18 September 2023
Authors: Dr Cristina URECHE (Business Development Manager at ABL Europe) and Guillaume SIRGUE (Head of Biomanufacturing and Process Development Operations...
Read More
By Justine Chabrol
/ 29 August 2023
Author: Guillaume SIRGUE, Head of BioManufacturing and Process Development Operations, ABL, Lyon, France Article published in Chimica Oggi-Chemistry Today (July/August...
Read More
By admin
/ 18 July 2023
Author: Quentin BAZOT Adeno-associated virus (AAV) is a small virus used in gene therapy applications. The demand for AAV clinical...
Read More
By Justine Chabrol
/ 4 May 2023
Authors: Mégane Denu, Bioproduction Engineer, Polyplus Quentin Bazot, Viral Vector Manufacturing and Process Development Specialist, ABL Europe Introduction Adeno-associated virus...
Read More
By admin
/ 24 March 2023
Internal promotion marks key milestone in company’s expansion and starting point for new roadmap focused on upstream and downstream R&D...
Read More
By Justine Chabrol
/ 25 October 2022
Deal offers developers in cell and gene therapy streamlined access to plasmid DNA and viral vector manufacturing in new, flexible...
Read More
By Justine Chabrol
/ 18 October 2022
Process optimization and manufacturing collaboration will advance development of candidates based onImugene’s chimeric pox vaccinia platform CF33 up to later phase...
Read More
By Justine Chabrol
/ 11 July 2022
Manufacturing collaboration will give KaliVir access to ABL’s long- term expertise in smallpox and oncolytic viruses through adherent platform manufacturing Rockville,...
Read More
By Justine Chabrol
/ 9 June 2022
Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process...
Read More
